Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites.

@article{VadhanRaj1988PhaseIT,
  title={Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites.},
  author={Saroj Vadhan-Raj and Carlos Cordon-Cardo and E A Carswell and David Mintzer and L Dantis and C Duteau and Mary Agnes Templeton and Herbert Friedrich Oettgen and Lloyd J. Old and Alan N. Houghton},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1988},
  volume={6 10},
  pages={1636-48}
}
Twenty-one patients were entered into a phase I trial to evaluate toxicity, antitumor effects, and biological responses at tumor sites during treatment of R24, an immunoglobulin G3 (IgG3) mouse monoclonal antibody (mAb) against GD3 ganglioside. Toxicity was related to dose of R24. Urticaria and pruritus were the most prominent side effects, with nausea, vomiting, and diarrhea occurring at the highest dose levels. Partial responses were observed in four patients lasting from 6 to 46 weeks, and… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Urticaria and pruritus were the most prominent side effects , with nausea , vomiting , and diarrhea occurring at the highest dose levels .
Urticaria and pruritus were the most prominent side effects , with nausea , vomiting , and diarrhea occurring at the highest dose levels .
Urticaria and pruritus were the most prominent side effects , with nausea , vomiting , and diarrhea occurring at the highest dose levels .
Urticaria and pruritus were the most prominent side effects , with nausea , vomiting , and diarrhea occurring at the highest dose levels .
Urticaria and pruritus were the most prominent side effects , with nausea , vomiting , and diarrhea occurring at the highest dose levels .
Urticaria and pruritus were the most prominent side effects , with nausea , vomiting , and diarrhea occurring at the highest dose levels .
Twenty - one patients were entered into a phase I trial to evaluate toxicity , antitumor effects , and biological responses at tumor sites during treatment of R24 , an immunoglobulin G3 ( IgG3 ) mouse monoclonal antibody ( mAb ) against GD3 ganglioside .
All Topics